Adc Therapeutics SA Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $79.6M+12.3% YoYTTM through 30 Jun 2026
Net Income -$96.9MTTM through 30 Jun 2026
Free Cash Flow -$102.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 92.9% |
| EBITDA Margin | -123.8% |
| Operating Margin | -131.8% |
| Net Margin | -121.8% |
Returns
-76.8%ROE
-44.1%ROA
Balance Sheet Health
Debt / Equity-0.62x
Current Ratio3.03x
Net Debt-$145.8Mnet cash position
Cash & Equivalents$219.1M
Quality Metrics
Altman Z-Score-8.40
Piotroski F-Score2 / 9
FCF Margin-128.5%
Rule of 40-126.9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $81.4M
Diluted EPS-$0.58TTMFY2025: $-1.12
Dividend
No dividend
Capital Allocation
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| ZYNLONTA Product Sales | $73.6M | +6.2% | View detailsThe company expects acceleration in net product revenue growth beginning in 2027, driven by potential clinical catalysts and expanded indications. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.